Inhibitor nucleic acids

• US 20050136430A1
• Filed: 07/15/2004
• Published: 06/23/2005
• Est. Priority Date: 07/15/2003
• Status: Abandoned Application

• Current Assignee: California Institute of Technology
• Original Assignee: California Institute of Technology
• Inventors: Davis, Mark E.
• Application Number:
  US10/892,527
• Publication Number:
  US 20050136430A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: A61L 2300/258 Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
• CPC Class Codes: A61L 2300/606 Coatings
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 15/111 General methods applicable to biologically active non-coding nucleic acids
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12N 2310/315 Phosphorothioates
• CPC Class Codes: C12N 2310/53 partially self-complementary or closed
• CPC Class Codes: C12N 2320/32 Special delivery means, e.g. tissue-specific
• CPC Class Codes: C12N 2320/51 modulating the chemical stability, e.g. nuclease-resistance

Abstract

The present invention provides methods and compositions for attenuating expression of a target gene in vivo. In general, the method includes administering RNAi constructs (such as small-interfering RNAs (i.e., siRNAs) that are targeted to particular mRNA sequences, or nucleic acid material that can produce siRNAs in a cell), in an amount sufficient to attenuate expression of a target gene by an RNA interference mechanism. In particular, the RNAi constructs include one or more modifications to improve serum stability and cellular uptake and to avoid non-specific effect.

Claims

1. A double-stranded nucleic acid for inhibiting expression of a target gene by an RNA interference mechanism, comprising:

a) a DNA sense polynucleotide strand comprising one or more modifications or modified nucleotides; and

b) an RNA antisense polynucleotide strand having a designated sequence that hybridizes to at least a portion of a transcript of the target gene and is sufficient to inhibit expression of the target gene.

2. The double-stranded nucleic acid of claim 1, wherein the DNA sense polynucleotide comprises a phosphorothioate moiety.

3. The double-stranded nucleic acid of claim 1, wherein the one or more modifications increase the isoelectric pH (pI) of the double-stranded nucleic acid relative to an unmodified double-stranded nucleic acid having the designated sequence by at least 0.5 units.

4. The double-stranded nucleic acid of claim 1, wherein the DNA strand comprises at least 50% modified nucleotides.

5. The double-stranded nucleic acid of claim 1, wherein the DNA strand comprises 100% modified nucleotides.

6. The double-stranded nucleic acid of claim 1 comprising one or more mismatched base pairs.

7. The double-stranded nucleic acid of claim 6, wherein the Tm of the double-stranded nucleic acid under physiological ionic strength is lower than the Tm of a nucleic acid comprising the same RNA antisense polynucleotide strand complemented by a perfectly matched DNA sense polynucleotide strand under physiological ionic strength.

8. The double-stranded nucleic acid of claim 1, wherein 50% or fewer of the nucleotides of the antisense polynucleotide are modified nucleotides.

9. The double-stranded nucleic acid of claim 1, wherein the one or more modifications increase the hydrophobicity of the double-stranded nucleic acid relative to an unmodified double-stranded nucleic acid having the designated sequence.

10. The double-stranded nucleic acid of claim 9, wherein the one or more modifications increase the hydrophobicity of the double-stranded nucleic acid relative to an unmodified double-stranded nucleic acid having the designated sequence by at least 1 logP unit.

11. The double-stranded nucleic acid of claim 1, wherein the double-stranded nucleic acid is a hairpin nucleic acid that is processed to an siRNA inside a cell.

12. The double-stranded nucleic acid of claim 1, wherein the double-stranded nucleic acid is 19-100 base pairs long.

13. The double-stranded nucleic acid of claim 1, wherein the double-stranded nucleic acid is internalized by cultured cells in the presence of 10% serum to a steady state level that is at least twice that of the unmodified double-stranded nucleic acid having the same designated sequence.

14. The double-stranded nucleic acid of claim 1, wherein the double-stranded nucleic acid has a serum half-life in a human or mouse of at least twice that of the unmodified double-stranded nucleic acid having the same designated sequence.

15. A pharmaceutical preparation for delivery of an RNAi nucleic acid to an organism, the composition comprising a pharmaceutically acceptable carrier and a double-stranded nucleic acid, comprising:

a) a DNA sense polynucleotide strand comprising one or more modifications or modified nucleotides; and

b) an RNA antisense polynucleotide strand having a designated sequence that hybridizes to at least a portion of a transcript of a target gene and is sufficient to inhibit expression of the target gene.

16. The preparation of claim 15, further comprising a polypeptide.

17. The preparation of claim 16, wherein the polypeptide is a serum polypeptide.

18. The preparation of claim 16, wherein the polypeptide is a cell targeting polypeptide.

19. The preparation of claim 18, wherein the cell targeting polypeptide is a polypeptide comprising a plurality of galactose moieties for targeting to hepatocytes.

20. The preparation of claim 18, wherein the cell targeting polypeptide is a transferrin polypeptide for targeting to neoplastic cells.

21. The preparation of claim 18, wherein the cell targeting polypeptide is an antibody that binds selectively to a cell of interest.

22. The preparation of claim 15, wherein the pharmaceutically acceptable carrier is selected from pharmaceutically acceptable salts, ester, and salts of such esters.

23. A pharmaceutical package comprising the pharmaceutical preparation of claim 15, in association with instructions for administering the preparation to a human patient.

24. A method for decreasing the expression of a target gene in a cell, the method comprising contacting the cell with a composition comprising a double-stranded nucleic acid, the double-stranded nucleic acid comprising:

a) a DNA sense polynucleotide strand comprising one or more modifications or modified nucleotides; and

b) an RNA antisense polynucleotide strand having a designated sequence that hybridizes to at least a portion of a transcript of the target gene and is sufficient to inhibit expression of the target gene.

26. The method of claim 24, wherein the cell is contacted with the double-stranded nucleic acid in the presence of at least 0.1 milligrams/milliliter of protein.

27. The method of claim 24, wherein the cell is contacted with the double-stranded nucleic acid in the presence of at least 10% serum.

28. The method of claim 24, wherein the cell is contacted with the double-stranded nucleic acid in the presence of a physiological concentration of protein.

29. The method of claim 24, wherein the composition further comprises a protein.

30. The method of claim 29, wherein the protein is a serum protein.

31. The method of claim 29, wherein the protein is an internalization protein and/or a targeting protein.

25. A method for decreasing the expression of a target gene in one or more cells of a subject, the method comprising administering to the subject a composition comprising a double-stranded nucleic acid, the double-stranded nucleic acid comprising:

a) a DNA sense polynucleotide strand comprising one or more modifications or modified nucleotides; and

b) an RNA antisense polynucleotide strand having a designated sequence that hybridizes to at least a portion of a transcript of the target gene and is sufficient to inhibit expression of the target gene.

32. A coating for use on a surface of a medical device, comprising a polymer matrix having RNAi constructs dispersed therein, which RNAi constructs are eluted from the matrix when implanted at site in a patient'"'"'s body and alter the growth, survival or differentiation of cells in the vicinity of the implanted device, wherein at least one of the the RNAi constructs is a double-stranded nucleic acid comprising:

a) a DNA sense polynucleotide strand comprising one or more modifications or modified nucleotides; and

b) an RNA antisense polynucleotide strand having a designated sequence that hybridizes to at least a portion of a transcript of the target gene and is sufficient to inhibit expression of the target gene.

33. The coating of claim 32, wherein the medical device is selected from a screw, plate, washers, suture, prosthesis anchor, tack, staple, electrical lead, valve, membrane, catheter, implantable vascular access port, blood storage bag, blood tubing, central venous catheter, arterial catheter, vascular graft, intraaortic balloon pump, heart valve, cardiovascular suture, artificial heart, pacemaker, ventricular assist pump, extracorporeal device, blood filter, hemodialysis unit, hemoperfasion unit, plasmapheresis unit, and filter adapted for deployment in a blood vessel.

34. The coating of claim 32, wherein the medical device is a stent.

35. The coating of claim 32, further comprising a protein that associates with the double-stranded nucleic acid.

36. A method of optimizing an RNAi construct for pharmaceutical uses comprising:

a) identifying an RNAi construct having a designated sequence which inhibits the expression of a target gene in vivo;

b) designing one or more modified RNAi constructs having the designated sequence and comprising one or more modified nucleic acids;

c) testing the one or more modified RNAi constructs of (b) for uptake into cells and/or serum half-life;

d) conducting therapeutic profiling of the RNAi constructs of (a) and (b) for efficacy and toxicity in animals;

e) selecting one or more modified RNAi constructs having desirable uptake properties and desirable therapeutic properties; and

f) formulating a pharmaceutical preparation including one or more RNAi constructs selected in step (e).

38. The method of claim 36, including an additional step of establishing a distribution system for distributing the pharmaceutical preparation for sale, and (optionally) establishing a sales group for marketing the pharmaceutical preparation.

37. A method of optimizing an RNAi construct for pharmaceutical uses comprising:

a) identifying an siRNA construct having a designated sequence which inhibits the expression of a target gene in vivo;

b) making RNAi constructs by replacing the sense RNA polynucleotide strand of the siRNA constructs of a) with a sense DNA polynucleotide strand that hybridizes with the antisense RNA strand of a);

c) testing the RNAi constructs of b) for uptake into cells and/or serum half-life;

d) conducting therapeutic profiling of the RNAi construct of b) for efficacy and toxicity in animals;

e) selecting one or more modified RNAi constructs by repeating steps a)-d) having desirable uptake properties and desirable therapeutic properties; and

f) formulating a pharmaceutical preparation including one or more RNAi constructs selected in step e).

39. A method of optimizing an RNAi construct comprising:

a) generating a plurality of test RNAi constructs, each of the construct comprising a double-stranded nucleic acid that comprises;

i) a DNA sense polynucleotide strand comprising one or more modifications or modified nucleotides;

ii) an RNA antisense polynucleotide strand.

b) determining gene silencing effect of the test RNAi constructs.

40. The method of claim 39 further comprising determining serum stability of the test RNAi constructs and selecting one or more test RNAi constructs having the desired gene silencing effect and serum stability.

41. The method of claim 39 further comprising determining cellular uptake of the test RNAi constructs and selecting one ore more test RNAi constructs having the desired gene silencing effect and cellular uptake properties.

42. The method of claim 39 further comprising formulating a pharmaceutical preparation including the selected test RNAi construct.

43. The method of claim 39, including an additional step of establishing a distribution system for distributing the pharmaceutical preparation for sale, and (optionally) establishing a sales group for marketing the pharmaceutical preparation.